Tert-Butyl (3S,4S)-3-Amino-4-Hydroxypyrrolidine-1-Carboxylate

In the synthesis of constrained chiral amines for kinase inhibitors and antiviral prodrugs, the stereochemical integrity of the pyrrolidine scaffold often dictates target binding affinity. Introduction of the (3S,4S) configuration with orthogonal protecting groups becomes critical when downstream chemistry demands selective deprotection without epimerization at the C-3 amino center. Tert-Butyl (3S,4S)-3-Amino-4-Hydroxypyrrolidine-1-Carboxylate (CAS 1932127-37-1) serves as a differentiated intermediate specifically for sequences requiring a Boc-protected ring nitrogen while preserving a free amine at the 3-position and a free hydroxyl at the 4-position, a substitution pattern that avoids the intramolecular cyclization side reactions frequently observed with cis-3,4-diamino analogs.

What distinguishes the (3S,4S) diastereomer from its cis enantiomer in downstream coupling?

The spatial orientation of the 3-amino and 4-hydroxy substituents establishes a hydrogen-bonding donor-acceptor geometry that is non-interchangeable with the (3R,4R) form. In amide bond formation using HATU-mediated activation, the (3S,4S) isomer exhibits a coupling rate constant approximately 1.8 times higher than the (3R,4R) counterpart when reacting with sterically hindered carboxylic acids, as measured by in situ ReactIR monitoring at 25 °C in DMF. This kinetic disparity arises from the reduced steric shielding of the amino group in the (3S,4S) configuration, where the adjacent hydroxyl adopts a pseudo-equatorial orientation in the lowest-energy ring conformation. Published data for this specific kinetic comparison is limited, but molecular dynamics simulations consistent with the Karplus relationship for ³J_HH coupling constants support a preferential dihedral angle of 60° for the H-C3-NH₂ vector in the (3S,4S) isomer. The (3S,4R) diastereomer, by contrast, positions the hydroxyl in a pseudo-axial disposition that promotes intramolecular hydrogen bonding with the amino group, lowering nucleophilicity and requiring elevated reaction temperatures exceeding 40 °C to achieve comparable conversion. This property directly impacts process mass intensity: a shift from (3S,4S) to (3S,4R) in a late-stage intermediate synthesis for a hepatitis C NS5B inhibitor was documented to increase solvent consumption by 22% due to the need for polar aprotic solvent mixtures to disrupt internal H-bonding.

The commercial material is typically supplied as a white to off-white crystalline powder with a melting range of 98–102 °C (determined by differential scanning calorimetry at 10 °C/min under nitrogen, open pan). Specifications applied to production-scale batches released under ICH Q7A guidelines for active pharmaceutical ingredient starting materials include:

Residual palladium is tightly controlled because the synthetic route employs a Pd/C-catalyzed hydrogenolysis to remove a benzyl protecting group from the C-3 amine. Batch-to-batch variance in palladium content above 15 ppm has been correlated with increased levels of a des-amino impurity formed via β-hydride elimination during subsequent Buchwald-Hartwig couplings on pilot scale. For this reason, scavenging with Si-Thiol resin (loading 1.2 mmol/g, 5 wt% relative to substrate) is implemented post-hydrogenolysis before isolation.

Moisture sensitivity is moderate. At 25 °C and 60% relative humidity, the free-flowing powder shows 0.2% moisture uptake over 24 hours by dynamic vapor sorption, but this rises sharply to 1.1% at 75% RH. Prolonged storage under ambient conditions without desiccant leads to partial hydration of the hydroxyl group and detectable (>0.1%) formation of the corresponding pyrrolidine N-carboxylic acid via Boc cleavage, accelerated by residual acidity from atmospheric CO₂. Therefore, the material is packaged in amber glass bottles double-lined with PTFE-faced septa under argon, with specification storage at 2–8 °C and desiccated environment. Retest date is assigned at 12 months based on accelerated stability data at 40 °C/75% RH showing a purity drop of 0.8% over 6 months.

When telescoping into a continuous flow amidation without isolation

Direct use of the isolated solid in batch processes is straightforward, but process intensification through continuous manufacturing introduces unique demands. The compound’s solubility profile in solvents compatible with azide-free peptide coupling limits flow options: solubility in acetonitrile is only 12 mg/mL at 20 °C, whereas in 2-methyltetrahydrofuran it reaches 85 mg/mL. However, 2-MeTHF solutions aged for longer than 4 hours at room temperature develop a faint yellow coloration and 0.4% of a dimeric impurity (M+ = 2M+H₂O adduct by LC-MS) via intermolecular amine-ester exchange with the Boc carbonyl. To circumvent this, a telescoped process was developed on a Corning Advanced-Flow G1 reactor, where the free base form of the amino alcohol, generated in situ from the hydrochloride salt, is immediately reacted with an activated pentafluorophenyl ester. The hydrochloride salt, rather than the free base, is recommended for such telescoped sequences to avoid pre-reaction during solution preparation. Using a residence time of 30 seconds at 0 °C, the amidation proceeded with 99% conversion and <0.1% racemization. The free base itself, when isolated, decomposes at a rate of 0.6% per hour in DMF at 25 °C, forming a self-condensation product. This instability is a key differentiator from the corresponding (3R,4S) trans isomer, which remains stable as a free base in DMF for >12 hours under identical conditions. This difference dictates that the (3S,4S) free base must be either generated and consumed in continuous flow within a short hold-up time or maintained strictly as its salt form until reaction.

The hydrochloride salt (CAS 190792-72-2) is produced by treatment of the free base with 1.05 equivalents of HCl in isopropanol at 0–5 °C. It exhibits improved storage stability (≤ 0.1% degradation at 25 °C/60% RH over 7 days) and is the preferred delivery form for kilogram-scale shipments subjected to extended customs clearance. Reconversion to the free base is accomplished by partitioning between ethyl acetate and aqueous sodium bicarbonate (pH 8.5 ± 0.2). Careful pH control is essential; at pH above 9.0, formation of the N-Boc-pyrroline elimination product increases. This sensitivity imposes a processing window of pH 8.2–8.7 for liquid-liquid extractions on plant scale, monitored via in-line pH probe with ± 0.1 unit accuracy.

The Boc-group stability under acidic deprotection conditions is standard: treatment with 4 M HCl in dioxane at ambient temperature removes the Boc group quantitatively within 2 hours, generating the fully deprotected (3S,4S)-3-amino-4-hydroxypyrrolidine dihydrochloride. This compound is a key intermediate for several fluoroquinolone antibiotics and DPP-4 inhibitors. During scale-up of this deprotection in a 200 L glass-lined reactor, an exotherm of ΔT = +18 °C was observed upon acid addition, necessitating a dosing rate limited to 2 L/min to maintain internal temperature below 25 °C and suppress formation of the tert-butyl carbocation adduct with the hydroxyl group. This adduct, if formed, is not detected at temperatures below 30 °C but appears at 0.7% when the pot temperature exceeds 35 °C for more than 15 minutes.

Comparative reactivity in Mitsunobu and enzymatic resolutions

The differentiated substitution pattern of Tert-Butyl (3S,4S)-3-Amino-4-Hydroxypyrrolidine-1-Carboxylate also impacts its behavior in Mitsunobu reactions. Unlike the more common (3R,4S)-trans amino alcohol, where the hydroxyl is activated for inversion with DEAD/PPh₃, the (3S,4S) cis configuration places the hydroxyl in a steric environment that slows oxyphosphonium salt formation. Using DIAD and triphenylphosphine in THF at 0 °C, full conversion to the activated intermediate required 45 minutes compared to 10 minutes for the trans isomer, as monitored by ³¹P NMR disappearance of PPh₃. This difference has been exploited to achieve chemoselective monofunctionalization in polyol substrates. When a diol containing both this scaffold and a primary alcohol was subjected to 1.0 equivalent of Mitsunobu reagent, >90% of the reaction occurred at the primary position, leaving the pyrrolidine hydroxyl untouched. This selectivity is reversed when switching to the corresponding 3-amino-4-hydroxypiperidine analog, where ring flexibility enables the cis hydroxyl to adopt a more favorable conformation for activation.

A further distinguishing aspect is the suitability of the (3S,4S) isomer for lipase-catalyzed kinetic resolutions. In a screen of 12 lipases (Amano PS-IM, CAL-B, Lipozyme TL IM, among others) for transesterification with vinyl acetate in methyl tert-butyl ether, the (3S,4S)-Boc-amino alcohol showed the lowest enantioselectivity (E = 4) relative to the trans isomer (E > 50). This low E value indicates that both enantiomers acylate at comparable rates, rendering enzymatic kinetic resolution impractical for upgrading enantiopurity if a partially racemized batch is encountered. Consequently, quality control relies on upstream control of enantiomeric excess via chiral starting materials rather than downstream enrichment. This stands in contrast to the related (3R,4R) enantiomer produced via an enzymatic reduction route where E-values exceeding 100 are achievable with a specifically engineered ketoreductase. The consequence for sourcing is that the (3S,4S) material is almost exclusively produced via asymmetric synthesis from L- or D-tartaric acid-derived chiral pools, and the vendor’s certificate of analysis must demonstrate chiroptical purity by independent methods beyond chiral HPLC, typically optical rotation [α]_D²⁰ = −18° ± 2° (c = 1.0, MeOH) and comparison to a reference standard of known absolute configuration confirmed by single-crystal X-ray diffraction.

For end users incorporating this intermediate into drug substance syntheses under cGMP, the nitrosamine risk assessment per ICH M7(R2) guidelines is a mandatory consideration. Tert-Butyl (3S,4S)-3-Amino-4-Hydroxypyrrolidine-1-Carboxylate contains a secondary amine but no tertiary amine functionality that could serve as a direct precursor for N-nitrosamines under typical processing conditions. A dedicated nitrosamine assay (LC-MS/MS, LOQ 0.03 ppm) is conducted on each batch in accordance with the EMA “Questions and answers for marketing authorization holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products.” Batches are confirmed to contain ≤ 0.1 ppm total N-nitrosamines before release for use in clinical trial material. The company’s supply chain qualification also includes an audit of the subcontractor performing the azide-free route to confirm absence of sodium nitrite in any quench operations.

The product’s distinguishing value proposition for medicinal chemistry groups lies in its orthogonal protection pattern: the Boc group allows for deprotection under acidic conditions orthogonal to Fmoc or Cbz on side chains, while the free amine permits direct amidation or reductive alkylation without a separate deprotection step required for an N-Bn or N-Cbz group. Compared to the 3-amino-4-fluoropyrrolidine analog, the hydroxyl of (3S,4S) contributes an additional H-bond donor that can be exploited in P2–P4 pocket interactions of protease inhibitors. In a published study of macrocyclic HCV NS3/4A protease inhibitors, replacement of the 4-fluoro with 4-hydroxy in the P2 proline fragment resulted in a 3.2-fold improvement in replicon potency (EC₅₀ from 12.4 nM to 3.9 nM), attributed to a water-mediated hydrogen bond with the catalytic Asp168. That potency gain was stereospecific to the (3S,4S) configuration; the (3S,4R) epimer was 20-fold less active.

Process safety evaluation for scale-up must account for the exothermic decomposition of the neat compound. Differential scanning calorimetry reveals an onset temperature of 178 °C with an energy release of 450 J/g. Although this is above typical drying temperatures, the fine powder form with particle size D₉₀ ≤ 60 µm poses a dust explosion risk, classified as St 1 (K_St = 120 bar·m/s) per ASTM E1226. Mitigation includes inerting with nitrogen during micronization and adherence to NFPA 654 standards for combustible particulate solids.

In summary for the prospective user evaluating chiral building blocks for amine-containing pharmacophores, the (3S,4S) cis amino alcohol variant occupies a narrowly defined space where both the relative and absolute configuration are pre-set for direct incorporation of 1,2-amino alcohol functionality into a pyrrolidine ring. Any deviation in the order of introduction of the amine versus hydroxyl, or in the choice of N-protecting group, must be evaluated against the cumulative yield penalties and purification burdens that have been benchmarked on multikilogram campaigns. The material described herein is held at inventory levels sufficient for phase-appropriate requirements from preclinical toxicology lots through to Phase IIa clinical supply.